Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

LESSONS LEARNED: Radiotherapy plus anti–PD‐1 antibody as first‐line therapy is safe and feasible in locally advanced esophageal squamous cell carcinoma (ESCC). Tumor‐infiltrating and peripheral lymphocytes were associated with patient survival. Further studies combining chemoradiotherapy with immuno...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Zhang, Wencheng, Yan, Cihui, Gao, Xuan, Li, Xiaoxia, Cao, Fuliang, Zhao, Gang, Zhao, Jingjing, Er, Puchun, Zhang, Tian, Chen, Xi, Wang, Yuwen, Jiang, Yao, Wang, Quanren, Zhang, Baozhong, Qian, Dong, Wang, Jun, Zhou, Dejun, Ren, Xiubao, Yu, Zhentao, Zhao, Lujun, Yuan, Zhiyong, Wang, Ping, Pang, Qingsong
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2021
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265339/
https://ncbi.nlm.nih.gov/pubmed/33893689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13797
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars